article · 1992
AMSA Combination ChernotheraDvId in Patients with Acute Myelogenous Leukemia Unsuitable for Standard Antileukemic Treatment
Forty-eight patients with acute myelogenous leukemia (AML) not eligible for anthracycline or mitoxantrone treatment, mostly due to cardiac contraindications,...
1 citationsDOI: https://doi.org/10.3109/10428199209051016